Oregon Board of Pharmacy alarmed the public about the widespread trading of mislabeled drugs – in the form of synthetic opioids
and synthetic fentanyl – which is widely being sold as heroin. Although the effect of these designer drugs is the same as that of heroin, this is still considered as illegal, as reported in a news release
The Controlled Substance Act (CSA) is a listing of drugs developed to be able to categorize and identify the acceptable usage of a drug or substance for medical use and the potential for dependence by an individual. There are 5 categories under this act, with the drug dependency level and abuse increasing as the category changes.
Under Schedule 1, drugs or substances have no medically accepted use and have a high potential for abuse. Among the drugs under this category are marijuana
(cannabis), lysergic acid diethylamide (LSD), methaqualone and methylenedioxymethamphetamine (ecstasy).
Schedule II are drugs or substances with high potential for abuse and may lead to severe psychological or physical dependence. Examples include dexidrine, fentanyl
Among the drugs stated above, fentanyl and heroin are being carefully monitored because of how these are being marketed in the U.S. in a different form. Heroin has a high market value, which means that only those who really have the money can purchase it. What happens now is that these drugs are being manufactured in China and are sold to the U.S. and in different countries in combination with other drugs, making them more dangerous to use.
Drug manufacturers either mislabel these substances as high-grade heroin so that they can be sold at a much higher price or add another chemical substance to give that extra “kick”, which with heroin alone may not be as potent.
These designer drugs
have been able to penetrate into different countries and are widely sold, affecting a lot of people and eventually becoming the number one killer among young popular celebrities and athletes.
These drugs are now being added to the schedule of Oregon's substances so that enforcers have a basis to prosecute those involved with trade and possession of these designer drugs.